“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
“There’s an electricity of discovery here like Genentech and Amgen,” said Dr. Herman. “AbSci’s ability to fold proteins is an innovative art form. This technology enables more efficient manufacturing, which will bring down the price of drugs.”